Drawing for Serial No. 90438594

USPTO serial 90438594

Serial No. 90438594

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
SCHMIDT, JOHN JOSEPH
Law office
DIVISIONAL UNIT

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with Serial No. 90438594?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Zhi Dong

Zhi Dong HAMRE, SCHUMANN, MUELLER & LARSON, P.C.45 SOUTH SEVENTH STREET, SUITE 2700MINNEAPOLIS, MN 55402United States

Goods and services

ClassDescriptionStatusFirst use
005Biological preparations for medical purposes, namely, gene modified immune cell therapies for the treatment of cancers, autoimmune diseases, inflammatory diseases, hypersensitivity, transplantation rejection, infectious diseases and neurodegenerative diseases; biological preparations for veterinary purposes for the treatment of cancers, autoimmune diseases, inflammatory diseases, hypersensitivity, transplantation rejection, infectious diseases and neurodegenerative diseases; biological tissue cultures for medical purposes, namely, human blood samples, human allograft tissues, human umbilical cord blood and human induced pluripotent stem cells (iPSCs) from somatic cells; biological tissue cultures for veterinary purposes, namely, animal blood samples, tumors and allograft tissues; blood for medical purposes; cultures of microorganisms for medical or veterinary use; diagnostic biomarker reagents for medical purposes, namely, chemical and biological reagents for medical or veterinary purposes; diagnostic preparations for medical purposes; diagnostic preparations for veterinary purposes; pharmaceuticals, namely, drugs for medical purposes, namely, for treating cancers, autoimmune diseases, inflammatory diseases, and neurodegenerative diseases; enzymes for medical purposes; enzymes for veterinary purposes; immunostimulants; medicinal infusions for treating cancers, autoimmune diseases, inflammatory diseases, and neurodegenerative diseases; pharmaceuticals, namely, medicines for human purposes, namely, for treating cancers, autoimmune diseases, inflammatory diseases, and neurodegenerative diseases; pharmaceuticals, namely, medicines for veterinary purposes, namely, for veterinary cancers; preparations of microorganisms for medical or veterinary use, namely, cultures of bacteria and viruses for medical or veterinary use; pharmaceutical preparations for treating cancers, autoimmune diseases, inflammatory diseases, and neurodegenerative diseases; pharmaceutical preparations, namely, gene modified immune cell therapies for the treatment of cancers, autoimmune diseases, inflammatory diseases, hypersensitivity, transplantation rejection, infectious diseases and neurodegenerative diseases; pharmaceuticals, namely, gene modified immune cell therapies for the treatment of cancers, autoimmune diseases, inflammatory diseases, hypersensitivity, transplantation rejection, infectious diseases and neurodegenerative diseases; pharmaceuticals in the nature of pharmaceutical preparations for treating cancers, autoimmune diseases, inflammatory diseases, and neurodegenerative diseases; transplants comprised of living cells, namely, genetically engineered tissues for medical and transplant purposes; genetically engineered cells for medical purposes, specifically for transplantation purposes; vaccinesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Oct 8, 2025MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Oct 8, 2025ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jul 24, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 19, 2024EX5GSOU EXTENSION 5 GRANTED—
Jul 19, 2024EXT5SOU EXTENSION 5 FILED—
Jul 19, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 2, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 31, 2024EX4GSOU EXTENSION 4 GRANTED—
Jan 31, 2024EXT4SOU EXTENSION 4 FILED—
Jan 31, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 29, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 27, 2023EX3GSOU EXTENSION 3 GRANTED—
Jul 27, 2023EXT3SOU EXTENSION 3 FILED—
Jul 27, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 3, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 1, 2023EX2GSOU EXTENSION 2 GRANTED—
Feb 1, 2023EXT2SOU EXTENSION 2 FILED—
Feb 1, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 28, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 26, 2022EX1GSOU EXTENSION 1 GRANTED—
Jul 26, 2022EXT1SOU EXTENSION 1 FILED—
Jul 26, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 25, 2022NOACCORRECTED NOA E-MAILED—
May 24, 2022DPCCDIVISIONAL PROCESSING COMPLETE—
Apr 25, 2022AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Apr 6, 2022DRRRDIVISIONAL REQUEST RECEIVED—
Apr 6, 2022ERTDTEAS REQUEST TO DIVIDE RECEIVED—
Feb 8, 2022NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Dec 14, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 14, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 24, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 10, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 9, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 8, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 8, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 2, 2021GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 2, 2021GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 2, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 1, 2021DOCKASSIGNED TO EXAMINER—
Mar 30, 2021MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Mar 28, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 4, 2021NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance